It can occur as a result of degeneration, dystrophy, trauma, inflammation or malignant diseases.[7] No dystrophy was observed in the fundus imaging of the patient, nor was it present in his family history. Clomiphene citrate, a selective oestrogen receptor modulator, is the first therapy in the pharmacological treatment of ovulation induction. Keywords: Anti vascular endothelial growth factor; choroidal neovascularization; clomiphene citrate; ovulation induction therapy EN Anti vascular endothelial growth factor choroidal neovascularization clomiphene citrate ovulation induction therapy 806 808 3 09/07/23 20230901 NES 230901 Introduction Clomiphene citrate (CC) has been the drug of choice for ovulation induction for many years. Reported ocular adverse events include: retinal vein occlusions,[2] bilateral uveitis,[3] illusory palinopsias[4] and maculopathy.[5] A case is presented of secondary choroidal neovascularization in a patient associated with ovulation-induction therapy with CC. [Extracted from the article]